PF-04518600

DRUG3 trials

Sponsors

Pfizer

Conditions

Advanced CancerGESELECTEERDE LOKAAL GEVORDERDE OF GEMETASTASEERDE CARCINOMEN SELECTED LOCALLY ADVANCED OR METASTATIC CANCERSNeoplasms

Phase 1

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

CompletedNCT02315066

PfizerNeoplasms

Start: 2015-04-23End: 2020-11-12Updated: 2022-04-21

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

TerminatedNCT02554812

PfizerAdvanced Cancer

Start: 2015-11-09End: 2023-03-23Updated: 2024-07-30

Unknown Phase

A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS

PfizerGESELECTEERDE LOKAAL GEVORDERDE OF GEMETASTASEERDE CARCINOMEN SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS

Target: 50Updated: 2024-02-28

Related Papers

Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies

Journal of Immunotherapy and Precision Oncology2023-11-249 citations

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2022-10-0152 citations

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

Clinical Cancer Research2021-10-0699 citations

P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort

Poster presentations2020-04-0112 citations

Analysis of OX40 agonist antibody (PF-04518600) in patients with hepatocellular carcinoma.

Journal of Clinical Oncology2020-02-019 citations

Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)

Annals of Oncology2018-10-013 citations

Abstract CT010: Pharmacodynamic (PD) changes in tumor RNA expression and the peripheral blood T cell receptor (TCR) repertoire in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600)

Cancer Research2018-07-011 citations

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

2017-10-23590 citations

The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600).

Journal of Clinical Oncology2017-05-2020 citations

First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.

Journal of Clinical Oncology2016-05-2033 citations

Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study.

Journal of Clinical Oncology2016-05-208 citations